Get the Stockscreener App
5.12
10.34%
0.48
After Hours:
5.12
Third Harmonic Bio Inc stock is traded at $5.12, with a volume of 549.19K.
It is up +10.34% in the last 24 hours and down -54.16% over the past month.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
See More
Previous Close:
$4.64
Open:
$4.63
24h Volume:
549.19K
Relative Volume:
2.28
Market Cap:
$230.70M
Revenue:
-
Net Income/Loss:
$-32.74M
P/E Ratio:
-6.2439
EPS:
-0.82
Net Cash Flow:
$-24.89M
1W Performance:
-4.30%
1M Performance:
-54.16%
6M Performance:
-53.58%
1Y Performance:
-44.10%
1-Day Range:
$4.625
$5.285
1-Week Range:
$4.62
$5.56
52-Week Range:
$4.62
$16.94
Third Harmonic Bio Inc Stock (THRD) Company Profile
Name
Third Harmonic Bio Inc
Sector
Industry
Phone
(209) 727-2457
Address
1700 MONTGOMERY STREET, SAN FRANCISCO
Compare THRD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
THRD
Third Harmonic Bio Inc
|
5.12 | 230.70M | 0 | -32.74M | -24.89M | -0.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-09-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-07-24 | Initiated | Raymond James | Outperform |
| Dec-16-22 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-10-22 | Initiated | Cowen | Outperform |
| Oct-10-22 | Initiated | Jefferies | Buy |
| Oct-10-22 | Initiated | Morgan Stanley | Overweight |
View All
Third Harmonic Bio Inc Stock (THRD) Latest News
Soho House, Third Harmonic Bio, and More Stocks See Action From Activist Investors - MSN
Where are the Opportunities in (THRD) - Stock Traders Daily
Third Harmonic Bio stock hits 52-week low at $5.58 - MSN
Haoxi Health Technology announces 1-for-25 reverse share split; shares plummet - MSN
GENERAL ATLANTIC, L.P. Acquires Additional Shares in Third Harmo - GuruFocus.com
Sionna, Odyssey join queue of biotechs testing investors’ IPO interest - BioPharma Dive
Trend Tracker for (THRD) - Stock Traders Daily
Papaya Growth Opportunity Stock Hits All-Time High of $12.5 - MSN
Jefferies cuts Third Harmonic stock target to $7 from $15 By Investing.com - Investing.com Canada
Third Harmonic Bio shares drop to lowest since 2023 By Investing.com - Investing.com Canada
Third Harmonic Bio stock hits 52-week low at $8.04 - Investing.com India
Dermata Therapeutics Inc (DRMA): Major Improvements, Worth A Look - Stocks Register
Stifel maintains positive outlook on Celldex and Third Harmonic stocks By Investing.com - Investing.com Canada
Revance gains as it plans to enter talks with Teoxane on likely superior bid (RVNC:NASDAQ) - Seeking Alpha
Learn to Evaluate (THRD) using the Charts - Stock Traders Daily
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Revance Therapeutics jumps after Teoxane offers $3.60 a share (NASDAQ:RVNC) - Seeking Alpha
Eton acquires Wilson disease drug Galzin (ETON:NASDAQ) - Seeking Alpha
Neumora stock drops on depression trial failure (NMRA:NASDAQ) - Seeking Alpha
Trading (THRD) With Integrated Risk Controls - Stock Traders Daily
Aquestive receives FDA Orphan Drug Exclusivity for Libervant - Seeking Alpha
Long Term Trading Analysis for (THRD) - Stock Traders Daily
Third Harmonic Bio's SWOT analysis: oral KIT inhibitor stock shows promise - Investing.com Australia
Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress - Investing.com India
Stock Market Analysis & Tools for Investors - Seeking Alpha
Third Harmonic Bio's SWOT analysis: stock outlook brightens on clinical progress By Investing.com - Investing.com South Africa
Dimension gets $500M to bankroll biotech’s convergence with tech - BioPharma Dive
Atlas Venture Announces $450 Million Fund XIV - Yahoo Finance
How the (THRD) price action is used to our Advantage - Stock Traders Daily
Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference - Marketscreener.com
Third Harmonic Bio to Present at Evercore HealthCONx Conference in December | THRD Stock News - StockTitan
Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade - MSN
Aclaris stock soars for second day on licensing deal, analyst upgrades (NASDAQ:ACRS) - Seeking Alpha
Amylyx Pharmaceuticals upgraded to Outperform at Baird, shares rise (NASDAQ:AMLX) - Seeking Alpha
(THRD) Technical Pivots with Risk Controls - Stock Traders Daily
RA Capital Management Reduces Stake in Third Harmonic Bio Inc - GuruFocus.com
Significant Stake Increase by T. Rowe Price in Third Harmonic Bi - GuruFocus.com
Revance Therapeutics jumps after Crown Laboratories tender offer extended again - Seeking Alpha
Vertiv Rises 13% in a Month: Time for Investors to Buy the Stock? - MSN
Shiba Inu (SHIB) Price Rises 53% but Hits Rejection at Key Ascending Resistance Level - MSN
Canopy Growth stock on watch after Q2 results (CGC:NASDAQ) - Seeking Alpha
Third Harmonic Bio Reports Q3 2024 Financial Results - TipRanks
Third Harmonic Bio Inc (THRD) Quarterly 10-Q Report - Quartzy
Third Harmonic Bio (THRD) to Present at Major Stifel, Jefferies Healthcare Conferences | THRD Stock News - StockTitan
Marquis Who's Who Honors Jonathan Colon, PhD, for Expertise in Biotechnology - 24-7 Press Release
Third Harmonic Flat on Q3 Results - Baystreet.ca
Third Harmonic Bio Announces Third Quarter 2024 Financial Results - The Manila Times
Third Harmonic Bio Reports $296M Cash Position, Phase 1 Trial Progress Despite Wider Q3 Loss | THRD Stock News - StockTitan
An RNAi renaissance is creating a new generation of startups - BioPharma Dive
(THRD) Technical Data - Stock Traders Daily
Third harmonic bio sees $14.3 million in stock sales by BVF Partners - Investing.com India
Third Harmonic Bio Inc Stock (THRD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):